Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

Background: COVID-19 patients are at high thrombotic risk. The safety and efficacy of
different anticoagulation regimens in COVID-19 patients remain unclear. Methods: We …

Background COVID‐19 disease‐related coagulopathy and thromboembolic complication,
an important aspect of the disease pathophysiology, are frequent and associated with poor …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Abstract Introduction Coronavirus disease (COVID‐19) is associated with a high incidence
of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

At this time last year, it was farfetched if not impossible to think of the immense changes and
challenges to people and the society in 2020. Social distancing has become the norm in …

Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …

Background: Anticoagulation is generally used in hospitalized patients with coronavirus
disease 2019 (COVID-19) as thromboprophylaxis. However, results from different studies …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …